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Malignant gliomas are the most common primary brain 
tumors in adults1 and are among the most aggressive malig-
nant tumors in part because of their propensity to dissemi-
nate diffusely throughout the brain.2 Therefore, to improve 
our ability to treat patients with malignant gliomas, we 
must increase our understanding of the migratory and inva-
sive properties of these tumors.
To migrate, glioma cells must acquire a special asym-
metric, and polarized phenotype. This enables them to 
transform intracellular forces into net cell body transloca-
tion.3 Typically, a migrating glioma cell remodels its cyto-
skeleton and forms protrusions and focal adhesions at the 
leading edge of the migratory front. This generates contrac-
tile forces and traction, allowing the cell body to move for-
ward. Recent studies have demonstrated that individual 
cells of certain cancers, such as melanoma, have 2 different 
interchangeable modes of movement: a mesenchymal mode 
driven by Rac GTPase activation and an amoeboid mode 
driven by Rho GTPase activation.4-6 Therefore, the ability 
of tumor cells to switch between different modes of 
migration might limit the effectiveness of single therapeutic 
agents targeting migration and invasion of cancer cells.
Supplementary material for this article is available on the Genes & Cancer 
website at http://ganc.sagepub.com/supplemental.
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Abstract
The malignant glioma is the most common primary human brain tumor, and its migration and invasiveness away from the primary tumor mass are 
considered a leading cause of tumor recurrence and treatment failure. Recently, gene expression profiling revealed that the transmembrane glycoprotein 
CD99 is more highly expressed in malignant glioma than in normal brain. Although its function is not completely understood, CD99 is implicated in cell 
adhesion and migration in a variety of different cell types. CD99 has wild-type and splice variant isoforms. Previous studies have shown that wild-type CD99 
may be an oncosuppressor in some tumors, distinct from the role of the splice variant isoform. In this study, our data reveal that only wild-type CD99 is 
expressed in human glioma cells and tissues. Using a tissue microarray, we validated that gliomas demonstrate higher expression of CD99 compared with 
nonneoplastic brain. To assess the role of CD99 in glioma migration and invasion, we inhibited CD99 expression by siRNA and demonstrated decreased 
glioma migration and invasion. In contrast, when CD99 was overexpressed in glioma cells, we observed enhancement of cell migration and invasiveness. 
An orthotopic brain tumor model demonstrates that CD99 overexpression significantly increases invasiveness and decreases survival rate. Interestingly, 
Rac activity was decreased and Rho activity was increased in CD99 overexpressing glioma cells, and the proportion of amoeboid cells to mesenchymal 
cells was significantly increased. Taken together, our findings suggest that CD99 may play an important role in the migration and invasion of human gliomas 
independent of Akt, ERK, or JNK signaling pathways. Moreover, CD99 might be involved in amoeboid-mesenchymal transition in glioma migration. CD99 
may be an important future target to inhibit migration and invasion, especially in CD99-expressing gliomas.
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Invasion is a complex cellular phenomenon that involves 
cell-to-cell and cell-to-extracellular matrix (ECM) interac-
tions, enzymatic degradation of the ECM, and cell migra-
tion.7 Cell movement involves the coordination of multiple 
signaling pathways that regulate cell-substratum adhesion 
and actin cytoskeletal dynamics.8
Therefore, numerous potential targets for migration and 
invasion in gliomas have been reported. Recently, through a 
gene-expression array study for possible immunotherapeu-
tic targets of gliomas, 31 novel potential membranous pro-
teins were revealed.9 One of these was CD99, whose 
expression was 4.8-fold higher than in normal brain. In 
addition, CD99 expression level directly correlated with 
advancing grade of glial tumors.
CD99, a cell surface glycoprotein with a molecular mass 
of 32 kDa, was originally described as a human thymus leu-
kemia antigen,10 a Ewing sarcoma-specific membrane 
marker molecule,11,12 and an adhesion molecule involved in 
spontaneous rosette formation of T cells with erythro-
cytes.13 CD99 is distributed on many cell types, with par-
ticularly strong expression on human cortical thymocytes, 
Ewing sarcoma, ependymoma, and peripheral primitive 
neuroectodermal tumors.12,14 Although the functional role 
of CD99 is not fully understood, in normal cells CD99 has 
been associated with cell adhesion, migration, apoptosis, 
differentiation, activation, and proliferation of lymphocytes 
and extravasation.15 In pathological conditions, the role of 
CD99 has not been completely elucidated. Expression of 
CD99 resulted in the induction of cell-cell adhesion and 
apoptosis16 and the inhibition of anchorage-independent 
growth, anoikis resistance, migration, and metastasis in 
Ewing sarcoma.17 Similar results were also reported in 
osteosarcoma.18 Contrary to this, others have reported that 
high expression of CD99 contributed to the malignant prop-
erties of sarcomas by promoting growth and migration.19
CD99 encodes 2 distinct proteins by alternative splicing 
of the CD99 gene transcript.20 Compared with the wild-type 
full-length form (CD99wt), the minor splicing variant 
(CD99sh) of molecular weight 28 kDa has a shortened 
intracytoplasmic fragment.15 Several papers suggest that 
the CD99sh favors oncogenesis, including anchorage-inde-
pendent growth, anoikis resistance, migration, and inva-
sion, whereas the CD99wt inhibits these phenomena in a 
few sarcomas.15,17 To the best of our knowledge, there are 
no published reports showing the expression and functional 
significance of CD99 in human gliomas. Accordingly, in 
the present study, we have examined the role played by 
CD99 in human glioma cells.
Results
CD99 expression in glioma cell lines and glioblastoma tissue 
samples. Western blot was performed on the different glioma 
cell lines, including U343, U251, U118, U87, SNB19, and 
T98, as well as on normal human astrocytes (NHAs). T98, 
SNB19, and U343 glioma cell lines expressed CD99 (Fig. 
1A), whereas NHAs, U251, U118 and U87 did not. From 
these results, we selected U87 for CD99 overexpression 
experiments because it expressed almost no CD99; we 
selected T98 and SNB19 glioma cells for gene silencing 
because these 2 cell lines demonstrated high levels of CD99 
expression. Five of 6 glioblastoma tissue samples showed 
high expression of CD99, whereas all 5 nonneoplastic brain 
specimens did not express this protein (Fig. 1B). To deter-
mine whether either of CD99 isoforms was expressed, we 
used 12% SDS-PAGE as previously described15,17; however, 
only CD99wt was expressed in the cell lines and tissues.
On the basis of the Western blot results for glioma cell 
lines, U343, T98, and SNB19 were selected for gradient 
RT-PCR analysis at different annealing temperatures using 
2 sets of primers that are specific for the CD99 isoforms. 
Consistent with the Western blot experiment, only CD99wt 
was expressed in these cell lines (Fig. 1C).
CD99 immunohistochemical detection using tissue microar-
ray analysis. The comparison of CD99 expression in differ-
ent grades of glioma revealed higher levels of expression in 
all grades of glioma compared with nonneoplastic brain 
(P = 0.004). In addition, Fig. 1D shows a representative tis-
sue microarray result in which the tumors and a nonneo-
plastic brain are scored. Quantification and statistical 
analysis demonstrate that CD99 expression is higher in 
tumor versus normal but is not significant between grades 
of glioma tumors (Fig. 1E) (P < 0.05).
CD99 localizes mainly to membrane of dynamic cells as well 
as motile cells. CD99 was expressed in both the membrane 
and the cytoplasm of glioma cells. In T98 and SNB19 cell 
lines, the leading edge of the cells or regions demonstrating 
cell-to-cell-contact showed enhanced expression of CD99 
(Fig. 2A).
Expression of CD99wt in stable transfectants of U87 
cells was confirmed using Western blot analysis (Fig. 2B, 
left panel). CD99 knockdown with the CD99 siRNA quad-
riplex could be demonstrated within 48 hours after siRNA 
transfection with nontargeting siRNA (NT-siRNA) used 
as a negative control. (Fig. 2B, right panel) and reached 
maximum effects at 72 hours after transfection (data not 
shown).
Immunofluorescence was used to examine the effects of 
CD99 modulation. CD99 localized to the periphery in the 
cell membrane, especially processes between glioma cells. 
In the nontargeting siRNA-transfected T98, SNB19, and 
stable CD99-pcDNA3.1-expressing cells, CD99 was local-
ized to the filopodia (Fig. 3). Interestingly, there was a 
decrease in the formation of filopodia and cell processes 
with predominantly flattened polygonal shaped cells in the 
CD99-depleted glioma cells.
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Figure 1.  Western blots show variable amounts of CD99 expression in different glioma cell lines, and NHA does not show the expression of CD99 
(A). Five of 6 glioblastoma tissue samples show relatively high expression of CD99, whereas all the 5 normal brains do not express this protein (B). The 
gradient RT-PCR analysis in different annealing temperature shows that only CD99wt was expressed (C). The representative tissue microarray images 
(TMA) from normal or varying grades of glioma tissue are shown (D). Quantification of tissue microarray demonstrates significant increase of CD99 in 
tumor compared with normal brain (E). TfR - Transferrin Receptor (loading control).
Alterations in CD99 expression levels do not significantly alter 
glioma cell viability, anchorage-independent growth, or resistance 
to anoikis. To determine the effect of stable CD99 expression 
on cell proliferation, an MTS assay was performed using 
U87 cells transfected with a CD99 expression vector con-
struct, EGFP, or empty vector controls. In addition, T98 and 
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SNB19 cells transfected with nontargeting siRNA (si-NT) 
or siRNA-CD99 were also investigated. As shown in Figure 
4A, no significant differences were observed between the 
samples.
To assess the effect of stable CD99 expression on 
the ability of glioma cells to grow in anchorage- 
independent conditions, we tested colony formation in 
soft agar using the stably transfected U87 cell line 
Figure 2.  Immunofluorescence shows that CD99 localizes mainly to membrane. In T98 and SNB19 cell lines, the leading edge or cell-to-cell-interacting 
membrane shows strong expression (A). Expression of CD99wt in the resultant stable transfectant clone of U87 cells was confirmed using Western blot. 
Stable control cell lines were also produced by the pcDNA3.1- empty vector and EGFP-pcDNA3.1- construct (B, left panel). CD99 knockdown with 
the CD99 siRNA quadriplex shows effects within 48 hours after siRNA transfection (B, right panel). Nontargeting siRNA (NT-siRNA) was used as a 
negative control.
Role of CD99 in glioma migration and invasion / Seol et al. 539
Figure 3.  Immunofluorescence shows that CD99 localizes to peripheral membrane, especially the connecting process between the cells or the filopodia 
in the nontargeting siRNA-transfected T98, SNB19, and stable CD99-pcDNA3.1-expressing cells. In contrast to these, the formation of filopodia and 
membrane processes are decreased, resulting in the polygonal appearance in CD99-depleted glioma cells.
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Figure 4.  There are no remarkable differences among the samples in MTS assays (A), colony formation assay in soft agar (B), and Anoikis assay (C).
(Fig. 4B). The empty vector control produced a mean 
number of 300 ± 46.4 colonies. The EGFP control and the 
U87-CD99-pcDNA3.1- cells produced 285 ± 30.6 and 
270 ± 55.3, respectively. No significant differences in 
anchorage-independent growth were observed in this 
assay.
In addition, to evaluate the resistance to anoikis of the 
stably-transfected cells, an anoikis assay was performed 
(Fig. 4C). The peak time to resistance was 48 hours in 
CD-99 transfected U87 cells, and no significant difference 
was observed among the EGFP and empty vector control 
cell lines (P > 0.05).
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Figure 5.  The adherence of U87 glioma cells to BCA and laminin is potentiated by the overexpression of CD99 (P = 0.0001 and 0.00002, respectively). In 
contrast, CD99 knockdown strongly inhibits glioma cells from adhering to the ECM substrate. In T98 glioma cells treated with CD99 siRNA, the adhesion 
to laminin is significantly decreased (laminin, P = 0.008). In SNB19 glioma cells treated with CD99 siRNA, the adhesion is significantly reduced on laminin 
(laminin, P = 0.009) (A). The radial migration assays with the same ECM macromolecules as in the attachment assays show similar results to those of the 
attachment assay (B). In U87 glioma cells that overexpress CD99, invasiveness increases (P = 0.0005). In T98 and SNB19 glioma cells in which CD99 is 
knocked down, invasiveness decreases (P = 0.000004 and 0.002, respectively) (C).  
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Modulation of CD99 expression alters glioma cell adhesion 
to ECM. Overexpression of CD99 increased the adherence 
of U87 glioma cells to BCA and laminin (P = 0.0001 and 
0.00002, respectively). In contrast, CD99 knockdown 
strongly inhibited glioma cells from adhering to the ECM 
substrate (Fig. 5A). In T98 glioma cells treated with CD99 
siRNA, there was significantly decreased adhesion to lam-
inin (BSA, P = 0.06; and laminin, P = 0.008). In SNB19 
glioma cells treated with CD99 siRNA, adhesion was sig-
nificantly reduced on BSA and laminin (BSA, P = 0.015; 
and laminin, P = 0.009).
CD99 expression alters glioma migration. To investigate 
whether CD99 plays a role in the migratory process of 
human glioma cells, we used radial migration assays with 
the same ECM macromolecules as in the attachment assays 
described above. In stably CD99-transfected U87 glioma 
cells, the rate of migration was increased on both BSA and 
laminin (P = 0.0001 and P = 0.034, respectively), com-
pared with stably EGFP-transfected U87 glioma cells (Fig. 
5B). In CD99-siRNA-treated T98 glioma cells, the migra-
tion rate was decreased on laminin but not BSA (BSA, P = 
0.06; laminin, P = 0.008). Similarly, in SNB19 glioma 
cells, CD99 knockdown decreased the migration rate on 
laminin, but not BSA (BSA, P = 0.15; laminin, P = 0.009) 
(Fig. 5B).
CD99 expression alters glioma invasiveness. In U87 glioma 
cells that overexpressed CD99, invasiveness increased 
through Matrigel over controls (P = 0.0005) (Fig. 5C). In 
T98 glioma cells in which CD99 was knocked down, inva-
siveness was significantly decreased (P = 0.000004). Simi-
larly, in SNB19 in which CD99 was knocked down, 
invasiveness was decreased (P = 0.002) (Fig. 5C).
Orthotopic intracranial xenografts of stably transfected U87 
cell lines. Mice harboring intracerebral xenografts derived 
from U87 cells stably transfected with EGFP exhibited a 
mean overall survival (OS) after initial tumor engrafting of 
85 days. In contrast, mice with xenografts derived from the 
U87-CD99 overexpressing clone showed a mean OS of 41 
days. The difference in mean OS was significant (P = 
0.005) (Fig. 6A). By light microscopy, all the EGFP-
expressing xenografts (6/6) showed well-demarcated mar-
gins of tumor and an ipsilateral tumor location. In contrast 
to this, 5 of 7 mice with xenografts overexpressing CD99 
exhibited indistinct tumor margins (Fig. 6B). Interestingly, 
57.1% (4/7) of mice with tumors overexpressing CD99 
demonstrated contralateral hemispheric involvement. 
Although mean tumor size between controls and CD99 
overexpressing tumors was not significantly different, the 
actual measurement of tumor size in the CD99 overexpress-
ing xenografts was more problematic given the infiltrative 
pattern of tumor involvement. These data are summarized 
in Fig. 6C.
Mass spectrometry identifies multiple cytoplasmic CD99-
interacting proteins. We performed mass spectrometry to 
identify cytoplasmic interacting proteins within the cyto-
plasmic fraction of CD99wt overexpressing U87 protein 
lysates immunoprecipitated with CD99 antibody. The can-
didate list of putative CD99 cytoplasmic interacting part-
ners is shown in Table 1. Putative interacting proteins were 
more frequently identified in CD99 immunoprecipitations 
than in the IgG control. Of the identified proteins, capain-1 
is interesting given its role in cytoskeleton remodeling and 
may shed light on a potential mechanism of action of CD99 
signaling in glioma cells.
Akt, ERK, and JNK do not participate in CD99 signaling 
pathway. To investigate the functional role of CD99 in glio-
magenesis, we examined the involvement of kinases previ-
ously identified as important in CD99 signaling. We 
assessed the roles of Akt, ERK, and JNK following EGF 
stimulation of CD99 overexpressing cells. In this study, the 
expression of Akt, phospho-Akt, ERK, phospho-ERK, 
JNK, and phosphor-JNK was not increased in stably CD99-
transfected cells when compared with control cells (Suppl. 
Fig. 1), suggesting that Akt, ERK, and JNK are not signifi-
cantly involved in CD99 signaling in glioma cells.
Rac activity decreases and Rho activity increases in CD99 
overexpressing cells. Rac activity was assessed in stably CD99-
transfected U87 glioma cells and was found to be decreased 
compared with that of stably EGFP-transfected U87 glioma 
cells and wild-type U87 glioma cells. In contrast, Rho activ-
ity of stably CD99-transfected U87 glioma cells was found to 
be increased compared with controls (Fig. 7).
CD99 overexpressing cells form amoeboid cells in 3D colla-
gen culture. To assess cellular morphology and 3-dimen-
sional growth patterns of glioma cells following CD99 
transfection, we used a type I collagen matrix assay. Immu-
nofluorescence of the actin cytoskeleton for CD99 overex-
pressing cells showed a preponderance of amoeboid cells. 
The proportion of amoeboid-type cells to mesenchymal-
type cells was significantly higher in stably CD99-trans-
fected U87 cells than in U87-EGFP-pcDNA3.1-stable cells, 
U87-pcDNA3.1-stable cells, and wild-type U87 cells (P = 
0.001) (Fig. 8).
Discussion
In this study, we examined the biological role of CD99 in 
human malignant gliomas. We show that CD99 overexpres-
sion was associated with morphological alterations of 
Role of CD99 in glioma migration and invasion / Seol et al. 543
glioma cells, increased motility and invasion, and increased 
adhesiveness. In addition, Rac activity was decreased, and 
Rho activity increased following CD99 overexpression, 
suggesting a potential mechanism by which CD99 influ-
ences the actin cytoskeleton. Elimination of CD99 expres-
sion by siRNA led to the opposite effects predominantly.
Figure 6.  The overall survival is longer in mice harboring intracerebral xenografts derived from the U87 cells stably transfected with EGFP (85 days after 
initial tumor engrafting) than in mice with xenografts derived from the U87-CD99 clone (41 days) (P = 0.005) (A). Microscopically, all of the EGFP control 
xenografts show well-demarcated margin of tumor. In contrast to this, only 28.6% of CD99 xenografts exhibited clear tumor margins (B). In addition, all 
of the EGFP mice show ipsilateral involvedness of tumor, whereas 57.1% of CD99 mice revealed contralateral involvement (C).
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The role of CD99 in many tumors is still controversial. 
High CD99 expression has been shown in Ewing sarcoma, 
acute lymphoblastic lymphoma, synovial sarcoma, mesen-
chymal chondrosarcoma, and rhabdomyosarcoma.11,12,21-24 
A significant relationship between CD99-positive cells and 
the occurrence of local invasion and/or distant metastasis 
has been found in gastrointestinal and pulmonary neuroen-
docrine tumors.25 However, low expression of CD99 has 
also been associated with the development of pancreatic 
and gastric cancers.26,27 A recent report also showed that 
down-regulation of CD99 is associated with the metastatic 
phenotype of osteosarcoma.18 Meanwhile, in breast inva-
sive carcinomas, no significant association was found 
between CD99 immunoreactivity and the metastatic stages 
of the tumors.28 This discrepancy may be due not only to the 
difference in cancer types but also to the difference in the 
relative expression levels of the 2 CD99 isoforms.
Differential expression of alternative splice variants has 
been known to occur on both physiological and pathologi-
cal bases. CD99 isoforms have been found to be differen-
tially expressed in various human tumor cell lines and 
normal tissues.15 The general concept is that both isoforms 
exhibit different functions in malignancy. CD99sh was 
originally reported as an inhibitor for homotypic cell adhe-
sion of lymphocytes, whereas CD99wt acted as an inducer 
for cell adhesion.20 Previous studies have suggested that 
CD99wt is a potent oncosuppressor in osteosarcoma, 
because CD99-forced expression reduced resistance to 
anoikis and inhibited growth in soft agar as well as migra-
tion.18 In contrast, our studies showed that CD99wt-overex-
pressing glioma cells have similar ability of survival and 
progression compared with nonexpressing glioma cells. 
Furthermore, our in vivo data revealed that mice harboring 
xenografts overexpressing CD99 had a decreased survival 
rate and higher invasive profiles than did controls.
In tumors expressing CD99sh or CD99wt, it has 
been shown that CD99 signaling cascades include the 
JunD-FosB complex, which enhances the transcription of 
AP-1-responsive genes, such as MMP-9 and cell motility-
stimulating genes.15 Moreover, it was also reported that 
CD99 expression results in positive cross-talk between the 
epidermal growth factor receptor and Akt pathways, caus-
ing increased expression of JunD and FosB along with 
increased AP-1 activity. Interestingly, our data demon-
strated that Akt, ERK, and JNK were not activated in CD99 
overexpressing human glioma cells, perhaps because only 
CD99wt was expressed, and not CD99sh. In efforts to 
understand more completely what signaling pathways may 
be operational in CD99 overexpressing glioma cells, we 
performed mass spectrometry to identify cytoplasmic inter-
acting peptides, and we found some putative interactions 
worthy of further investigation, such as capain-1. MMP-9 
was increased, however, in keeping with previous studies 
showing its activation following CD99 up-regulation (data 
not shown).
Recently, 2 different migratory modes have been 
reported in certain types of cancer cells such as mela-
noma.5,6 One is mesenchymal migration, which is charac-
terized by an elongated morphology that requires 
extracellular proteolysis localized at cellular protrusions 
and is driven by activation of Rac. The other is amoeboid 
migration, which is characterized by round cells with no 
obvious polarity that is independent of proteases and is 
driven by activation of Rho.29 These 2 migratory modes are 
interconvertible, depending on environmental conditions. 
In our study, Rac activity was decreased and Rho activity 
was increased in stably CD99-transfected glioma cells, 
which enhanced migration and invasiveness of human 
malignant glioma cells. Moreover, the ratio of amoeboid 
cells to mesenchymal cells was much higher in CD99 over-
expressing glioma cells compared with control cells, further 
confirming a Rho-activated cell migratory phenotype and 
suggesting a potential mechanism by which CD99 may be 
associated with increased cellular migration. From our 
mass spectrometry analysis, potential CD99 interactors 
Capain1 and the 14-3-3 chaperone proteins may represent a 
potential mechanism as to how CD99 regulates Rac and 
Rho activation, as these proteins have been previously 
shown to influence Rac and Rho activity.30,31 Although the 
majority of the literature indicates that CDC42 and Rac are 
critical regulators of filipodia formation, there is evidence 
to suggest alternative mechanisms of filopodia activation 
through RhoA regulation, as demonstrated in this study and 
previous groups.32,33 Although beyond the scope of this 
study, genome-wide profiling of CD99 positive versus neg-
ative cells would be of interest to interrogate further mecha-
nisms by which CD99 promotes these invasive phenotypes 
in glioblastoma. 
In summary, we have demonstrated for the first time 
 expression and activation of CD99wt enhance the 
Table 1.  Candidate CD99 Interacting Proteins Identified by 
Mass Spectrometry
Identified Proteins CD99 IP IgG IP
Isoform 1 of CD99 antigen   6   1
Annexin A1 21 12
14-3-3 protein zeta/delta 13   8
L-lactate dehydrogenase β chain 10   6
IGL@ protein   3   0
29kDa protein   8   4
Cathepsin D   3   0
Capain-1 catalytic subunit   4   0
Collagen alpha-1 chain   3   0
Mass spectrometry (LC-MS/MS using LC system) was performed to 
identify cytoplasmic interacting proteins on the cytoplasmic fraction of 
CD99wt overexpressing U87 protein lysates immunoprecipitated with 
CD99 antibody. The candidate list of putative CD99 cytoplasmic interact-
ing partners is shown.
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migration and invasive ability of human glioma cells. CD99 
may play a role in in amoeboid-mesenchymal transition in 
glioma migration. Our findings suggest that CD99 could be 
an important target for tumor migra-
tion and invasion in those gliomas, 
which express CD99 and show 
enhanced invasiveness.
Materials and Methods
Cell lines, cell culture, and tissue sam-
ples of glioblastoma and normal brain. 
The permanent, well-characterized 
U343, U251, U118, SNB19, and T98 
human glioma cell lines were main-
tained in Dulbecco’s modified eagle’s 
medium (DMEM) with 10% fetal 
bovine serum (FBS) (HyClone Labo-
ratories, Inc., Logan, Utah). The U87 
cell line was maintained in minimum 
essential medium (MEM) supplemented with 10% FBS. 
Normal human astrocytes (NHAs) were maintained in 
ABM media containing 3% FBS 0.1% ascorbic acid, 0.5% 
recombinant human epidermal growth factor, 0.1% 
GA-1000, 0.25% insulin, and 1% L-glutamine (Clonetics, 
East Rutherford, New Jersey). Cells were cultured in a 
37°C, 5% CO
2
 humidified chamber. Tissue samples of 6 
glioblastoma and 5 normal brain samples were provided 
from the brain tumor bank of the Toronto Western Hospital/
Labatt Brain Tumor Research Centre with Research Ethics 
Board approval.
Western blot analysis. Cell lysates were prepared by 
scraping 90% confluent 10-cm dishes into 1 mL of lysis 
buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM 
MgCl
2
, 1% Triton X-100, 10% glycerol, and protease inhib-
itors; Roche Molecular Biochemicals, Laval, Quebec). Tis-
sue samples were homogenized with cell lysis buffer. They 
were then centrifuged at 14,000 rpm to pellet the insoluble 
material. The protein concentrations of the cell lysates were 
determined using the MicroBCA kit (Pierce Biotechnology, 
Rockford, Illinois) according to the manufacturer’s direc-
tions. Twelve percent SDS-PAGE was used to separate 2 
isoform proteins. Proteins were transferred onto PVDF 
membrane (Immobilon-P, Millipore, Billerica, Massachu-
setts) and immunoblotted with primary antibodies over-
night at 4°C. For CD99 immunoblotting, mouse monoclonal 
anti-MIC2 (CD99) antibody (1:1000; Santa Cruz Biotech-
nology, Santa Cruz, California) was used. As a loading con-
trol on the same blot, a mouse monoclonal antibody against 
the human transferrin receptor (1:1000; Zymed Laborato-
ries, South San Francisco, California) was used.
Bound antibodies were visualized using horseradish per-
oxidase (HRP)-conjugated goat anti-mouse IgG (Bio-Rad 
Laboratories, Hercules, California) and analyzed using 
Western blot Luminol Reagent (PerkinElmer Life and Ana-
lytical Sciences, Waltham, Massachusetts).
Figure 7.  The Rac activity of stably CD99-transfected U87 glioma cells decreases compared with 
that of stably EGFP-transfected U87 glioma cells and wild-type U87 glioma cells (left panel). In 
contrast, the Rho activity of stably CD99-transfected U87 glioma cells increases (right panel).
Figure 8.  To check the cellular morphology and growth pattern in 
3-dimensional spaces, 3D culture using type I collagen matrix was used. 
The proportion of amoeboid-type cells (A and B) to mesenchymal-type 
cells (C and D) was significantly higher in stably CD99-transfected U87 
cells than in control cells (E, P = 0.001).
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Reverse-transcription PCR. Total cellular RNA was puri-
fied from the cultured cells using Trizol reagent (Invitro-
gen, Carlsbad, California). cDNA was prepared using 1 µg 
of total RNA, random hexamer primers, and the Omniscript 
RT kit (Qiagen, Valencia, California). Gradient (in different 
annealing temperatures) reverse transcription-PCR (RT-
PCR) was performed using Platinum Tag DNA Polymerase 
(Invitrogen) in an MJ Research PTC-200 thermal cycler 
(Bio-Rad Laboratories). To detect both CD99wt and 
CD99sh isoforms, the following primers were used (all 5′-
3′)17: forward GTGATCCCCGGGATTGTG; CD99wt 
reverse CTATTTCTCTAAAAGAGTACG; CD99sh reverse 
CCTAGGTCTTCAGCCATG. The sizes of the expected 
PCR products were 180 bp for CD99wt and 117 bp for 
CD99sh.
Tissue microarray and immunohistochemistry. Immunohis-
tochemical staining was done using the commercially avail-
able brain tumor tissue microarray GL803 (US Biomax, 
Inc., Rockville, Maryland), which consists of 55 astrocytic 
tumor specimens and 5 normal brain specimens. The patient 
population included 22 male and 33 female tumor speci-
mens, with a mean patient age of 41.7 years (range, 4-68), 
and 3 male and 2 female normal control specimens, with a 
mean patient age of 45.8 years (range, 30-52). Of the astro-
cytic tumor specimens, 6 were Grade I, 9 were Grade II, 25 
were Grade III, and 15 were Grade IV. Tumor grade data 
were provided by US Biomax, Inc., and were determined 
according to the 2007 WHO grading system.
The tissues were deparaffinized, endogenous peroxide 
was blocked using 3% hydrogen peroxide in methanol, and 
microwave antigen retrieval was done using Antigen 
Unmasking Solution (Vector Laboratories, Inc., Burlin-
game, California). Blocking was done using 10% normal 
horse serum, and endogenous biotin was blocked using an 
avidin/biotin kit (Vector Laboratories). The tissue and 
tumor sections were incubated with a mouse monoclonal 
anti-CD99 antibody (1:500; Santa Cruz Biotechnology), 
followed by a biotinylated secondary antibody (Vector Lab-
oratories) for 30 minutes and then a HRP-conjugated ultra-
streptavidin labeling reagent (ID Labs Biotechnology, Inc., 
London, Ontario) for 30 minutes. After thorough rinsing in 
PBS, color development was performed using freshly pre-
pared NovaRED solution (Vector Laboratories). Finally, 
sections were counterstained lightly with Meyer’s hema-
toxylin, dehydrated in alcohols, cleared in xylene, and 
mounted in Permount (Fisher Scientific, Ottawa, Ontario).
CD99 expression was then evaluated. Results of immu-
nostaining were graded semiquantitatively from 0 to 3 
using the following ranges; Grade 0, 0%; Grade I, 1–30%; 
Grade II, 31–70%; and Grade III, ≥71% positive tumor 
cells. Sections of Ewing sarcoma sample were used for 
positive control of immunoreactivity.
CD99 expression construct and stably overexpressing cell 
line. A plasmid containing full-length human CD99wt 
cDNA was obtained from the Mammalian Gene Collection 
(CD99-IRAU48-F10 in pOTB7). This cDNA was sub-
cloned into the pcDNA3.1-expression vector (Invitrogen) 
using PCR cloning techniques to generate EcoRI and 
BamHI restriction sites. The sequence was then verified. 
Empty pcDNA3.1 and an enhanced green fluorescent pro-
tein (EGFP)-pcDNA3.1 expression construct were used as 
negative controls. To produce stable transfectants, expres-
sion vectors were linearized, transfected into the U87 cell 
line using FuGene6 (Roche Applied Science, Laval, Que-
bec) reagent, and kept under G418 antibiotic selection. 
Transfected cells were subsequently plated into 96-well 
plates at 1 cell per well and expanded to obtain stably trans-
fected clones. Western blot verified the expression level of 
CD99 at the protein level.
siRNA preparation and transfections. For gene silencing, 
an siRNA quadriplex specific to CD99wt (NM_002414) 
Accell SMARTpool (Dharmacon, Thermo Scientific, 
Waltham, Massachusetts) was purchased. The target 
sequences were as follows: The first, corresponding to 
599th to 617th nucleotide (5′ TCTCTAGCTTCATT-
GCTTA); the second, corresponding to 903rd to 921st (5′ 
TTACTAACGATGAATTTTA); the third, corresponding to 
1183rd to 1201st (5′ TTTGTAGGGATATTTGTTT); and 
the fourth, corresponding to 1059th to 1077th (5′ 
CCAGAATCTTGGCTGTTTA). A commercial Accell 
nontargeting pool (Thermo Scientific) was used to evaluate 
off-target effects. Transient transfection was performed 
using the manufacturer’s protocol of Accell siRNA delivery 
media (Thermo Scientific). Maximal inhibition of protein 
was achieved by the third day after transfection, so the gli-
oma cells were assayed at 72 hours posttransfection.
Immunofluorescence and confocal microscopy. Cells were 
plated onto coverslips 24 hours after transfection. At 72 
hours after transfection, cells were washed 3 times with 
PBS, fixed with 4% paraformaldehyde and 750 µL of 1 M 
sucrose for 30 minutes, and then permeablized for 10 min-
utes using 0.2% Triton X-100 in PBS at room temperature. 
Nonspecific binding was blocked by 5% BSA in PBS for 30 
minutes at room temperature. Subsequently, cells were 
incubated with mouse monoclonal anti-CD99 antibody 
(1:100; Santa Cruz Biotechnology) for 30 minutes in a 
37°C incubator. After washing, cells were then incubated 
with Alexa Fluor 488 (1:200, Molecular Probes, Eugene, 
Oregon) conjugated goat anti-mouse IgG secondary anti-
body. For double labeling with F-actin, cells were coincu-
bated with Texas Red-X phalloidin (1:50; Molecular 
Probes). To visualize fluorescence, a Zeiss Axiovert 200M 
Spinning Disk confocal microscope (Carl Zeiss Inc.) 
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equipped with a Hamamatsu Back-Thinned EM-CCD cam-
era (Hamamatsu Corporation, Bridgewater, New Jersey) 
was used.
Cell viability assay. Cell viability was determined using the 
colorimetric MTS assay. Cells stably transfected with the 
CD99wt overexpression construct or with the CD99wt 
siRNA were trypsinized, counted, and resuspended 6 hours 
after transfection. The cells were plated in 96-well dishes at 
a density of 2,000 cells per well and allowed to adhere over-
night. To assess viability, cells were tested in 5 replicates 
using MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt (Promega Corporation, Madison, Wisconsin)]. Absor-
bance at 490 nm was measured 2 hours after the addition of 
20 µL of MTS reagent per well, every 24 hours over a 
96-hour period.
Colony formation assay in soft agar. A base layer of 1.5% 
agar/2× DMEM/FBS was prepared in 35-mm plates. Upper 
layer agar was made using 1.5% agar, 2× DMEM, FBS, and 
sterile water and kept in liquid phase in a 42°C water bath. 
Cells were resuspended in 0.75% agar/DMEM/FBS and 
overlaid on the base layer with 2,000 cells per 35-mm plate 
and subsequently kept in a humidified chamber at 37°C for 
2 weeks. Plates were stained with crystal violet, and the 
numbers of colonies in triplicate plates were counted.
Anoikis (detachment-induced apoptosis in poly-2 hydroxy-
ethyl methacrylate) assay. Cells undergoing death by anoikis 
were identified and quantified using the CytoSelect anoikis 
assay kit according to the manufacturer’s instructions (Cell 
Biolab, San Diego, California). Briefly, cells to be assayed 
for anoikis were collected, pelleted by centrifugation, and 
resuspended in culture medium. Cells (400,000) in suspen-
sion were added to an anchorage-resistant poly-Hema-
coated well. After 24-hour, 48-hour, and 72-hour incubation 
times at 37°C, 50 µL of MTT reagent in the kit was added 
into each well to detect living cells. Absorbance at 570 nm 
was measured 2 hours after the addition of MTT reagent.
Cell attachment assay. The cell attachment assay was per-
formed as described previously (Elbashir, 2001 #46; Srira-
marao, 1993 #47) with some modifications. Briefly, 96-well 
plates were incubated at 4°C overnight with an ECM pro-
tein, laminin (at 10 µg/mL). The unbound sites were blocked 
with 0.1% BSA in PBS for 1 hour at 37°C. Control dishes 
were prepared by blocking with BSA alone. Glioma cells 
were detached, resuspended in serum-free medium, and 
then plated at 5 × 104 cells/well on laminin- or BSA-coated 
plates. The cells were allowed to adhere for 3 hours at 37°C 
and 5% CO
2
 in a humidified chamber. Unattached 
cells were removed by washing with PBS 3 times, and the 
remaining cells were fixed with 4% paraformaldehyde and 
stained with 0.5% crystal violet. Excess stain was washed 
away with water, and then the plates air-dried overnight. 
The crystal violet bound to the attached cells was solubi-
lized with 1% SDS, and a microtiter plate reader (Molecu-
lar Devices, Sunnyvale, California) measured the 
absorbance of each well at 595 nm. All experiments were 
repeated 3 times using replicates of 5.
Radial cell migration assay. Cell migration assays were 
performed using the microliter-scale radial monolayer 
assay as described previously.34,35 Briefly, 10-well Teflon-
coated slides (CSM Inc., Phoenix, Arizona) were coated 
with different ECM proteins and 0.1% BSA as described 
above. To establish a circular confluent monolayer 1 mm in 
diameter at the center of the substrate-coated well, trans-
fected cells were collected 24 hours after transfection and 
seeded through a cell sedimentation manifold (CSM Inc.) at 
2,000 cells per well. Photographs were taken 22 hours after 
plating, and a circle of best-fit circumscribing the cells was 
drawn. The cells were allowed to migrate for 24 hours, and 
then another circle circumscribing the newly migrated cells 
was made. The average migration rate was calculated as the 
change in the diameter of the circle circumscribing the cell 
population over a 24-hour period (micrometers per 24 
hours). Photomicrographs were taken with an inverted 
microscope (Leica DM IRE2; Leica Microsystems, Inc., 
Bannockburn, Illinois) and studied using image-analysis 
software (Scion Image, Frederick, Maryland). All experi-
ments were repeated 3 times using 3 replicates each.
Transwell cell invasion assay. A cell invasion assay was 
carried out using modified Boyden chambers that consisted 
of Transwell-coated Matrigel membrane filter inserts with 8 
µm pores in 24-well tissue culture plates (BD Biosciences, 
Bedford, Massachusetts) as described previously.36 Two 
days after transfection, 4 × 104 cells were plated onto the 
top of the chamber in DMEM with 5% FBS. The bottom 
chamber was filled with DMEM containing 20% FBS as a 
chemoattractant. Plates were incubated for 24 hours in a 5% 
CO
2
 humidified chamber at 37°C. Noninvading cells were 
wiped off the upper surface of the membrane with a cotton 
swab, and the filter membrane was fixed with 4% parafor-
maldehyde and stained with 0.5% crystal violet. The degree 
of invasion was determined by counting the number of cells 
that had migrated through the membrane in at least 6 ran-
dom fields (total magnification, 200×) per filter. Experi-
ments were repeated 3 times in triplicate.
Orthotopic intracranial xenograft. U87 cells stably trans-
fected with EGFP-pcDNA3.1- and CD99wt-pcDNA3.1- 
expression constructs were used for xenograft experiments. 
Cells were released from the culture plates using Accutase 
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(Sigma-Aldrich, St. Louis, Missouri), washed twice in 1 × 
PBS, resuspended in a small volume of serum-free EMEM 
at a final concentration of 100,000 cells/µL, and kept on ice 
until the time of injection. Male Nu/Foxn1/Nu mice (ages 
5-6 weeks; Charles River, Senneville, Quebec) were anes-
thetized using i.p. ketamine/xylazine. Intracranial injection 
of 200,000 cells (2 µL) was performed in the right forebrain 
at the following coordinates: 2.0 mm lateral and 1 mm ante-
rior to bregma at a 2.0 mm depth from the skull surface, 
using a murine stereotactic head frame and Hamilton 
syringe. Six mice were injected with U87 cells stably trans-
fected with EGFP-pcDNA3.1-, and 7 mice were injected 
with U87-CD99-pcDNA3.1- stable cell line. Mice were 
observed for evidence of a symptomatic intracranial mass 
such as incoordination, lethargy, or weight loss >20% of 
maximal body weight. Whole brain specimens were fixed 
in 10% formalin for 72 hours followed by 70% ethanol until 
all samples were obtained for further processing. Samples 
were paraffin embedded; sections were cut, mounted onto 
slides, and stained for H&E, human CD99, the same as in 
the tissue microarray.
Mass spectrometry. Eight µg of total cellular lysate of 
CD99wt overexpressing U87 cell lines was obtained using 
NP40 (50 mM Tris-HCL, 150 mM NaCl, and 1% NP-40) 
lysis buffer. Then 4 µg of cell lysate was subjected to immu-
noprecipitation with 8 µg of mouse monoclonal anti-MIC2 
(CD99) antibody or normal mouse IgG antibody (Santa 
Cruz Biotechnology), respectively. The samples were 
loaded onto 12% 1.0 mm Tris gels for SDS-PAGE, and the 
gels were stained with Colloidal Blue Staining Kit (Invitro-
gen) per the manufacturer’s instruction. The gels were then 
sent to the Advanced Protein Technology Centre at the Hos-
pital for Sick Children (Toronto) and subjected to liquid 
chromatography–mass spectrometry (LC/MS) using an LC 
system (Easy-nLC, Proxeon Biosystems A/S, Odense) cou-
pled with an LTQ-Orbitrap mass spectrometer (Thermo 
Scientific, Bremen, Germany). The data were analyzed 
using SCAFFOLD 3 software (Proteome Software, Port-
land, Oregon).
Epidermal growth factor (EGF) stimulation for CD99 overex-
pressing cells. The cell lines were stimulated with 100 ng/mL 
EGF for 10 minutes after serum starvation for 24 hours, and 
cell lysates were obtained using lysis buffer. After standard-
ization of protein concentration, Western blotting analysis 
was performed using antibodies to Akt (1:1000; Cell 
Signaling Technology, Danvers, Massachusetts), phospho-
Akt(Ser473) (1:1000; Cell Signaling Technology), 
ERK1/2 (1:1000; Cell Signaling Technology), phospho-
ERK1/2(Thr202/Tyr204) (1:2000; Cell Signaling Technology), 
JNK (1:500; Millipore, Temecula, California), and phos-
pho-JNK(Thr183/Tyr185) (1:500; Millipore).
Rac and Rho GTPase Activation Assay. Rac and Rho pull-
down assays were performed using protein lysates of cell 
lines and GTPase Activation Assay Kit (Millipore) per the 
manufacturer’s directions. Then samples were subjected to 
10% SDS-PAGE and Western blot analysis.
Three-dimensional (3D) collagen cultures and immunofluo-
rescence. Glioma cells (1 × 105 cells/mL) were suspended in 
1.4 µg/mL Type I collagen Cultrex gels (Trevigen, Gaithers-
burg, Maryland) and incubated at 37°C for 48 hours. Then 
the collagen gels were fixed with 4% paraformaldehyde for 
30 minutes at room temperature, permeablized using 0.2% 
Triton-X for 10 minutes, and stained with Alexa Fluor Phal-
loidin (1:40; Invitrogen, Eugene, Oregon) and H3343 
(1:10000; Invitrogen) after blocking with 5% BSA in PBS 
for 1 hour. The gels were imaged as described above.
Statistical analyses. Statistical analyses were performed 
using Student t test and the Mann-Whitney U test. Survival 
curves were generated Kaplan-Meier method. The log-rank 
statistic was used to compare the distributions of survival 
times. A P value of < 0.05 was considered statistically 
significant.
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